Review



anti pdgfra  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems anti pdgfra
    Anti Pdgfra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 724 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/Mouse+PDGF+R+alpha+Antibody/pm42803763-153-26-27
    Average 96 stars, based on 724 article reviews
    anti pdgfra - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Control:

    Article Title: Breast cancer remodels lymphatics in sentinel lymph nodes
    Article Snippet: VEGF-C (100-20CD), VEGF165 (100-20), M-CSF, GM-CSF, and G-CSF were obtained from Peprotech, and MGP (TP760483) was obtained from Origene. .. AACOCF3 (ab120350) was obtained from Abcam, fludarabine (S1491) from Seleckchem, antibodies targeting adrenomedullin (AF6108), EGF (AB-236NA), goat IgG control (AB-108-C), PDGF (AB-20-NA), rabbit IgG control (AB-105-C), and VEGF165 (AB-293-NA) from R&D Systems. .. Anti-MGP (A5439) was obtained from Abclonal, and anti-TGF-β (BE0057) and the mouse IgG1 isotype (BE0083) from BioXCell.

    other:

    Article Title: Functional characterisation of rare variants in genes encoding the MAPK/ERK signalling pathway identified in long-lived Leiden Longevity Study participants
    Article Snippet: Stimulation was performed by adding insulin (100 nM), PDGF (50 ng/mL or 100 ng/mL) (520-BB, RNDSystems, MN, USA), or EGF (25 ng/mL or 100 ng/mL) (E4127, Merck, Germany) to cells for 10, 30, and 2 min, respectively.

    Article Title: Establishment of bovine extraembryonic endoderm stem cells enables efficient blastoid formation
    Article Snippet: After three days, when all the ICMs attach and form outgrowth, change the medium to bXENM S containing DMEM: F12 and Neurobasal medium (1:1), 0.5x N2-supplement, 0.5x B27-supplement, 0.5x NEAA, 0.5x GlutaMAX, 0.1 mM 2-mercaptoethanol, 1mM NaPy (Sigma, s8636), 10 μg/mL L-ascorbic acid (Sigma, A92902), 1x ITS-X (Gibco, 51500–056), 0.1% FBS, 0.5% KSR, 20 ng/mL LIF (Peprotech, 300–05), 1 μM Chir99021 (Sigma, SML-1046), 10 ng/mL bFGF, 10 ng/mL ActivinA.



    Similar Products

    95
    MedChemExpress pdgf bb
    Oxamate inhibits <t>PDGF-BB-induced</t> PASMC proliferation and migration (A) Bright-field and immunofluorescence images of primary rat PASMCs stained for α-SMA. Scale bars: 100 μm. (B–F) PASMCs were treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. Representative western blots and quantitative analysis of H3K18la, PCNA, vimentin, and MCT4 expression. (G) Cell viability was assessed by CCK-8 assay after 24 h of treatment. Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.
    Pdgf Bb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/PDGF-BB%2C+Human/pmc13695137-20-0-2
    Average 95 stars, based on 1 article reviews
    pdgf bb - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Bioss pdgfr β
    Oxamate inhibits <t>PDGF-BB-induced</t> PASMC proliferation and migration (A) Bright-field and immunofluorescence images of primary rat PASMCs stained for α-SMA. Scale bars: 100 μm. (B–F) PASMCs were treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. Representative western blots and quantitative analysis of H3K18la, PCNA, vimentin, and MCT4 expression. (G) Cell viability was assessed by CCK-8 assay after 24 h of treatment. Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.
    Pdgfr β, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/PDGF+Receptor+beta+Polyclonal+Antibody/pm42856031-429-17-21
    Average 94 stars, based on 1 article reviews
    pdgfr β - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    MedChemExpress hyp7055
    Oxamate inhibits <t>PDGF-BB-induced</t> PASMC proliferation and migration (A) Bright-field and immunofluorescence images of primary rat PASMCs stained for α-SMA. Scale bars: 100 μm. (B–F) PASMCs were treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. Representative western blots and quantitative analysis of H3K18la, PCNA, vimentin, and MCT4 expression. (G) Cell viability was assessed by CCK-8 assay after 24 h of treatment. Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.
    Hyp7055, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/PDGF-BB%2C+Human/pm42885089-28-22-29
    Average 95 stars, based on 1 article reviews
    hyp7055 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress pdgfc
    Oxamate inhibits <t>PDGF-BB-induced</t> PASMC proliferation and migration (A) Bright-field and immunofluorescence images of primary rat PASMCs stained for α-SMA. Scale bars: 100 μm. (B–F) PASMCs were treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. Representative western blots and quantitative analysis of H3K18la, PCNA, vimentin, and MCT4 expression. (G) Cell viability was assessed by CCK-8 assay after 24 h of treatment. Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.
    Pdgfc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/PDGF-CC%2C+Mouse/pm42886559-730-23-18
    Average 94 stars, based on 1 article reviews
    pdgfc - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    RayBiotech inc canine pdgf bb elisa kit
    Oxamate inhibits <t>PDGF-BB-induced</t> PASMC proliferation and migration (A) Bright-field and immunofluorescence images of primary rat PASMCs stained for α-SMA. Scale bars: 100 μm. (B–F) PASMCs were treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. Representative western blots and quantitative analysis of H3K18la, PCNA, vimentin, and MCT4 expression. (G) Cell viability was assessed by CCK-8 assay after 24 h of treatment. Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.
    Canine Pdgf Bb Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/Canine+PDGF-BB+ELISA/10__3390_slash_ijms27209041-200-21-25
    Average 94 stars, based on 1 article reviews
    canine pdgf bb elisa kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc e cadherin
    SLC25A33 deficiency induces pericyte differentiation via mitochondrial ROS accumulation, which were regulated by the TGF‐β/Smad2 signaling pathway. (A) Flow cytometry analysis using MitoSOX Red shows increased mtROS production in SLC25A33‐suppressed HBVPs compared to control and SLC25A33‐overexpressing groups. (B) Quantification of mtROS fluorescence intensity confirms this increase. (C, D) qPCR analysis reveals upregulated α‐Sma and <t>downregulated</t> <t>E‐cadherin</t> mRNA levels in Slc25a33 ‐knockdown HBVPs. (E) Representative Western blot images of α‐SMA and E‐cadherin protein expression. (F, G) Densitometric quantification shows increased α‐SMA and decreased E‐cadherin protein levels. (H) qPCR analysis shows upregulated Tgfb1 mRNA in SLC25A33‐deficient HBVPs. (I–K) No significant changes are observed in Smad2 , Smad3 , or Smad4 mRNA levels among groups. (L) Representative western blots of TGF‐β, p‐Smad2, Smad2, p‐Smad3, Smad3, Smad4, and GAPDH. (M) TGF‐β protein levels are significantly elevated in the knockdown group. (N) Phosphorylated Smad2 (p‐Smad2) is markedly increased, indicating pathway activation. (O–R) No significant differences are detected in p‐Smad3, total Smad2, Smad3, or Smad4 protein expression. Control: HBVPs without treatment; SLC25A33 (−): HBVPs treated with LV‐ Slc25a33 ‐shRNA; SLC25A33 (+): HBVPs treated with LV‐ Slc25a33 ‐OE. Data are mean ± SEM; n = 3.
    E Cadherin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/PDGF+Receptor+beta+Rabbit+mAb/pmc13621939-109-35-36
    Average 96 stars, based on 1 article reviews
    e cadherin - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    R&D Systems anti pdgfra
    SLC25A33 deficiency induces pericyte differentiation via mitochondrial ROS accumulation, which were regulated by the TGF‐β/Smad2 signaling pathway. (A) Flow cytometry analysis using MitoSOX Red shows increased mtROS production in SLC25A33‐suppressed HBVPs compared to control and SLC25A33‐overexpressing groups. (B) Quantification of mtROS fluorescence intensity confirms this increase. (C, D) qPCR analysis reveals upregulated α‐Sma and <t>downregulated</t> <t>E‐cadherin</t> mRNA levels in Slc25a33 ‐knockdown HBVPs. (E) Representative Western blot images of α‐SMA and E‐cadherin protein expression. (F, G) Densitometric quantification shows increased α‐SMA and decreased E‐cadherin protein levels. (H) qPCR analysis shows upregulated Tgfb1 mRNA in SLC25A33‐deficient HBVPs. (I–K) No significant changes are observed in Smad2 , Smad3 , or Smad4 mRNA levels among groups. (L) Representative western blots of TGF‐β, p‐Smad2, Smad2, p‐Smad3, Smad3, Smad4, and GAPDH. (M) TGF‐β protein levels are significantly elevated in the knockdown group. (N) Phosphorylated Smad2 (p‐Smad2) is markedly increased, indicating pathway activation. (O–R) No significant differences are detected in p‐Smad3, total Smad2, Smad3, or Smad4 protein expression. Control: HBVPs without treatment; SLC25A33 (−): HBVPs treated with LV‐ Slc25a33 ‐shRNA; SLC25A33 (+): HBVPs treated with LV‐ Slc25a33 ‐OE. Data are mean ± SEM; n = 3.
    Anti Pdgfra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/Mouse+PDGF+R+alpha+Antibody/pm42803763-153-26-27
    Average 96 stars, based on 1 article reviews
    anti pdgfra - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology mouse antipdgf a
    SLC25A33 deficiency induces pericyte differentiation via mitochondrial ROS accumulation, which were regulated by the TGF‐β/Smad2 signaling pathway. (A) Flow cytometry analysis using MitoSOX Red shows increased mtROS production in SLC25A33‐suppressed HBVPs compared to control and SLC25A33‐overexpressing groups. (B) Quantification of mtROS fluorescence intensity confirms this increase. (C, D) qPCR analysis reveals upregulated α‐Sma and <t>downregulated</t> <t>E‐cadherin</t> mRNA levels in Slc25a33 ‐knockdown HBVPs. (E) Representative Western blot images of α‐SMA and E‐cadherin protein expression. (F, G) Densitometric quantification shows increased α‐SMA and decreased E‐cadherin protein levels. (H) qPCR analysis shows upregulated Tgfb1 mRNA in SLC25A33‐deficient HBVPs. (I–K) No significant changes are observed in Smad2 , Smad3 , or Smad4 mRNA levels among groups. (L) Representative western blots of TGF‐β, p‐Smad2, Smad2, p‐Smad3, Smad3, Smad4, and GAPDH. (M) TGF‐β protein levels are significantly elevated in the knockdown group. (N) Phosphorylated Smad2 (p‐Smad2) is markedly increased, indicating pathway activation. (O–R) No significant differences are detected in p‐Smad3, total Smad2, Smad3, or Smad4 protein expression. Control: HBVPs without treatment; SLC25A33 (−): HBVPs treated with LV‐ Slc25a33 ‐shRNA; SLC25A33 (+): HBVPs treated with LV‐ Slc25a33 ‐OE. Data are mean ± SEM; n = 3.
    Mouse Antipdgf A, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/PDGF-A+Antibody/10__1038_slash_s41531___026___01581___8-228-67-76
    Average 93 stars, based on 1 article reviews
    mouse antipdgf a - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology pdgf bb
    Demonstration of the effect of aPRP or PRGF on TGF-β <t>and</t> <t>PDGF-BB</t> expression in HCs and OACs at 2 or 3 h by ELISA. (A–D) TGF-β and (E–H) PDGF-BB expressions of 2.7% aPRP, 1.8% PGRF, or 4.3% L-PRP-administered HCs and OACs are given as mean standard deviation graphs for each time point in comparison with the control groups. One-way analysis of variance (ANOVA), Tukey’s HSD post hoc test (*): p < 0.05.
    Pdgf Bb, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgf/Human+PDGF-BB+(Platelet+Derived+Growth+Factor+BB)+ELISA+Kit/pmc13619922-88-6-8
    Average 94 stars, based on 1 article reviews
    pdgf bb - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Oxamate inhibits PDGF-BB-induced PASMC proliferation and migration (A) Bright-field and immunofluorescence images of primary rat PASMCs stained for α-SMA. Scale bars: 100 μm. (B–F) PASMCs were treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. Representative western blots and quantitative analysis of H3K18la, PCNA, vimentin, and MCT4 expression. (G) Cell viability was assessed by CCK-8 assay after 24 h of treatment. Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.

    Journal: iScience

    Article Title: Lactate-driven histone lactylation by AARS1 promotes pulmonary arterial hypertension

    doi: 10.1016/j.isci.2026.117911

    Figure Lengend Snippet: Oxamate inhibits PDGF-BB-induced PASMC proliferation and migration (A) Bright-field and immunofluorescence images of primary rat PASMCs stained for α-SMA. Scale bars: 100 μm. (B–F) PASMCs were treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. Representative western blots and quantitative analysis of H3K18la, PCNA, vimentin, and MCT4 expression. (G) Cell viability was assessed by CCK-8 assay after 24 h of treatment. Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.

    Article Snippet: PDGF-BB , Medchemexpress , Cat# HY-P7055.

    Techniques: Migration, Immunofluorescence, Staining, Western Blot, Analysis, Expressing, CCK-8 Assay

    AARS1 may act as a putative regulator of lactylation in PAH (A and B) Representative western blots and quantitative analysis of AARS1 protein expression in lung tissues from MCT-induced PAH rats treated with or without oxamate (750 mg/kg). Data are presented as mean ± SD ( n = 8 biological replicates for each group; one-way ANOVA). (C) Immunofluorescence staining of AARS1 in lung tissues from MCT-induced PAH rats with or without oxamate treatment. Scale bars: 20 μm. (D and E) Representative western blots and quantitative analysis of AARS1 expression in PASMCs treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. (F) Predicted structural model of lactate binding to the catalytic pocket of AARS1, with interacting residues indicated. (G–L) Representative western blots and quantitative analysis showing that siRNA-mediated knockdown of AARS1 attenuated the lactate-induced increases in AARS1, PCNA, and H3K18la levels in PASMCs. Data are presented as mean ± SD ( n = 4 biological replicates for each group; one-way ANOVA). (M) Immunofluorescence staining showing increased nuclear localization of AARS1 following lactate treatment in PASMCs. Scale bars: 25 μm. ∗ p < 0.05; ns, not significant.

    Journal: iScience

    Article Title: Lactate-driven histone lactylation by AARS1 promotes pulmonary arterial hypertension

    doi: 10.1016/j.isci.2026.117911

    Figure Lengend Snippet: AARS1 may act as a putative regulator of lactylation in PAH (A and B) Representative western blots and quantitative analysis of AARS1 protein expression in lung tissues from MCT-induced PAH rats treated with or without oxamate (750 mg/kg). Data are presented as mean ± SD ( n = 8 biological replicates for each group; one-way ANOVA). (C) Immunofluorescence staining of AARS1 in lung tissues from MCT-induced PAH rats with or without oxamate treatment. Scale bars: 20 μm. (D and E) Representative western blots and quantitative analysis of AARS1 expression in PASMCs treated with PDGF-BB (20 ng/mL) with or without oxamate (50 μM) for 24 h. (F) Predicted structural model of lactate binding to the catalytic pocket of AARS1, with interacting residues indicated. (G–L) Representative western blots and quantitative analysis showing that siRNA-mediated knockdown of AARS1 attenuated the lactate-induced increases in AARS1, PCNA, and H3K18la levels in PASMCs. Data are presented as mean ± SD ( n = 4 biological replicates for each group; one-way ANOVA). (M) Immunofluorescence staining showing increased nuclear localization of AARS1 following lactate treatment in PASMCs. Scale bars: 25 μm. ∗ p < 0.05; ns, not significant.

    Article Snippet: PDGF-BB , Medchemexpress , Cat# HY-P7055.

    Techniques: Western Blot, Analysis, Expressing, Immunofluorescence, Staining, Binding Assay, Knockdown

    Effects of oxamate on β-catenin expression and H3K18la enrichment at the Ctnnb1 promoter (A and B) Representative western blots and quantitative analysis of β-catenin expression in lung tissues from MCT-induced PAH rats treated with or without oxamate (750 mg/kg). Data are presented as mean ± SD ( n = 8 biological replicates for each group; one-way ANOVA). (C and D) Western blot analysis of β-catenin expression in PASMCs treated with PDGF-BB (20 ng/mL) in the presence or absence of oxamate (50 μM) for 24 h. (E) Relative Ctnnb1 mRNA expression in PASMCs treated with lactate (20 mM) in the presence or absence of oxamate (50 μM) for 24 h. (F and G) ChIP-qPCR analysis showing H3K18la enrichment at the promoter region of Ctnnb1 in PASMCs treated with lactate (20 mM) with or without oxamate (50 μM). Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.

    Journal: iScience

    Article Title: Lactate-driven histone lactylation by AARS1 promotes pulmonary arterial hypertension

    doi: 10.1016/j.isci.2026.117911

    Figure Lengend Snippet: Effects of oxamate on β-catenin expression and H3K18la enrichment at the Ctnnb1 promoter (A and B) Representative western blots and quantitative analysis of β-catenin expression in lung tissues from MCT-induced PAH rats treated with or without oxamate (750 mg/kg). Data are presented as mean ± SD ( n = 8 biological replicates for each group; one-way ANOVA). (C and D) Western blot analysis of β-catenin expression in PASMCs treated with PDGF-BB (20 ng/mL) in the presence or absence of oxamate (50 μM) for 24 h. (E) Relative Ctnnb1 mRNA expression in PASMCs treated with lactate (20 mM) in the presence or absence of oxamate (50 μM) for 24 h. (F and G) ChIP-qPCR analysis showing H3K18la enrichment at the promoter region of Ctnnb1 in PASMCs treated with lactate (20 mM) with or without oxamate (50 μM). Data are presented as mean ± SD ( n = 3–5 biological replicates for each group; one-way ANOVA). ∗ p < 0.05; ns, not significant.

    Article Snippet: PDGF-BB , Medchemexpress , Cat# HY-P7055.

    Techniques: Expressing, Western Blot, Analysis, ChIP-qPCR, Gene Expression

    Journal: iScience

    Article Title: Lactate-driven histone lactylation by AARS1 promotes pulmonary arterial hypertension

    doi: 10.1016/j.isci.2026.117911

    Figure Lengend Snippet:

    Article Snippet: PDGF-BB , Medchemexpress , Cat# HY-P7055.

    Techniques:

    SLC25A33 deficiency induces pericyte differentiation via mitochondrial ROS accumulation, which were regulated by the TGF‐β/Smad2 signaling pathway. (A) Flow cytometry analysis using MitoSOX Red shows increased mtROS production in SLC25A33‐suppressed HBVPs compared to control and SLC25A33‐overexpressing groups. (B) Quantification of mtROS fluorescence intensity confirms this increase. (C, D) qPCR analysis reveals upregulated α‐Sma and downregulated E‐cadherin mRNA levels in Slc25a33 ‐knockdown HBVPs. (E) Representative Western blot images of α‐SMA and E‐cadherin protein expression. (F, G) Densitometric quantification shows increased α‐SMA and decreased E‐cadherin protein levels. (H) qPCR analysis shows upregulated Tgfb1 mRNA in SLC25A33‐deficient HBVPs. (I–K) No significant changes are observed in Smad2 , Smad3 , or Smad4 mRNA levels among groups. (L) Representative western blots of TGF‐β, p‐Smad2, Smad2, p‐Smad3, Smad3, Smad4, and GAPDH. (M) TGF‐β protein levels are significantly elevated in the knockdown group. (N) Phosphorylated Smad2 (p‐Smad2) is markedly increased, indicating pathway activation. (O–R) No significant differences are detected in p‐Smad3, total Smad2, Smad3, or Smad4 protein expression. Control: HBVPs without treatment; SLC25A33 (−): HBVPs treated with LV‐ Slc25a33 ‐shRNA; SLC25A33 (+): HBVPs treated with LV‐ Slc25a33 ‐OE. Data are mean ± SEM; n = 3.

    Journal: Aging Cell

    Article Title: IGF ‐1/ SLC25A33 Maintains Blood‐Labyrinth Barrier Integrity by Suppressing TGF ‐β/Smad2‐Mediated Pericyte Activation in Age‐Related Hearing Loss

    doi: 10.1111/acel.70712

    Figure Lengend Snippet: SLC25A33 deficiency induces pericyte differentiation via mitochondrial ROS accumulation, which were regulated by the TGF‐β/Smad2 signaling pathway. (A) Flow cytometry analysis using MitoSOX Red shows increased mtROS production in SLC25A33‐suppressed HBVPs compared to control and SLC25A33‐overexpressing groups. (B) Quantification of mtROS fluorescence intensity confirms this increase. (C, D) qPCR analysis reveals upregulated α‐Sma and downregulated E‐cadherin mRNA levels in Slc25a33 ‐knockdown HBVPs. (E) Representative Western blot images of α‐SMA and E‐cadherin protein expression. (F, G) Densitometric quantification shows increased α‐SMA and decreased E‐cadherin protein levels. (H) qPCR analysis shows upregulated Tgfb1 mRNA in SLC25A33‐deficient HBVPs. (I–K) No significant changes are observed in Smad2 , Smad3 , or Smad4 mRNA levels among groups. (L) Representative western blots of TGF‐β, p‐Smad2, Smad2, p‐Smad3, Smad3, Smad4, and GAPDH. (M) TGF‐β protein levels are significantly elevated in the knockdown group. (N) Phosphorylated Smad2 (p‐Smad2) is markedly increased, indicating pathway activation. (O–R) No significant differences are detected in p‐Smad3, total Smad2, Smad3, or Smad4 protein expression. Control: HBVPs without treatment; SLC25A33 (−): HBVPs treated with LV‐ Slc25a33 ‐shRNA; SLC25A33 (+): HBVPs treated with LV‐ Slc25a33 ‐OE. Data are mean ± SEM; n = 3.

    Article Snippet: Sections were blocked in 10% goat serum + 0.3% Triton X‐100 in PBS for 1 h. Primary antibodies were applied overnight at 4°C: IGF‐1 (NOVUS, SPM406, 1:200), SLC25A33 (Bioss, bs‐21231R, 1:200), PDGFRβ (CST, #3169, 1:200), E‐cadherin (CST, #14472, 1:200), α‐SMA (Bioss, bs‐10196R, 1:200), TGFβ1 (Bioworld, BS80030, 1:50), p‐Smad2 (Bioworld, bs‐3419R, 1:500).

    Techniques: Flow Cytometry, Analysis, Control, Fluorescence, Knockdown, Western Blot, Expressing, Activation Assay, shRNA

    SLC25A33 modulates α‐SMA and E‐cadherin expression through the TGF‐β/Smad2 pathway in vivo. (A) Immunofluorescence staining shows α‐SMA (red) and E‐cadherin (green) expression in the stria vascularis. Nuclei are counterstained with DAPI (blue). (B, C) Quantification reveals increased α‐SMA and decreased E‐cadherin in the Slc25a33 ‐knockdown group ( n = 5, five typical sections from five individual mice were analyzed per group). (D, E) qPCR confirms upregulation of α‐Sma and downregulation of E‐cadherin mRNA levels in the Slc25a33 ‐knockdown group ( n = 3 mice). (F, G) TGF‐β and (H, I) p‐Smad2 immunoreactivity are enhanced in the knockdown group and reduced in the overexpression group ( n = 5, five typical sections from five individual mice were analyzed per group). (J) qPCR confirms upregulation of Tgf‐β mRNA levels in the knockdown group and downregulation levels in the overexpression group ( n = 3 mice). Control: wild‐type C57BL/6J mice without treatment; SLC25A33 (−): mice treated with AAV‐ie‐sh Slc25a33 ; SLC25A33 (+): mice treated with AAV‐ie‐ Slc25a33 ‐OE. Data are mean ± SEM.

    Journal: Aging Cell

    Article Title: IGF ‐1/ SLC25A33 Maintains Blood‐Labyrinth Barrier Integrity by Suppressing TGF ‐β/Smad2‐Mediated Pericyte Activation in Age‐Related Hearing Loss

    doi: 10.1111/acel.70712

    Figure Lengend Snippet: SLC25A33 modulates α‐SMA and E‐cadherin expression through the TGF‐β/Smad2 pathway in vivo. (A) Immunofluorescence staining shows α‐SMA (red) and E‐cadherin (green) expression in the stria vascularis. Nuclei are counterstained with DAPI (blue). (B, C) Quantification reveals increased α‐SMA and decreased E‐cadherin in the Slc25a33 ‐knockdown group ( n = 5, five typical sections from five individual mice were analyzed per group). (D, E) qPCR confirms upregulation of α‐Sma and downregulation of E‐cadherin mRNA levels in the Slc25a33 ‐knockdown group ( n = 3 mice). (F, G) TGF‐β and (H, I) p‐Smad2 immunoreactivity are enhanced in the knockdown group and reduced in the overexpression group ( n = 5, five typical sections from five individual mice were analyzed per group). (J) qPCR confirms upregulation of Tgf‐β mRNA levels in the knockdown group and downregulation levels in the overexpression group ( n = 3 mice). Control: wild‐type C57BL/6J mice without treatment; SLC25A33 (−): mice treated with AAV‐ie‐sh Slc25a33 ; SLC25A33 (+): mice treated with AAV‐ie‐ Slc25a33 ‐OE. Data are mean ± SEM.

    Article Snippet: Sections were blocked in 10% goat serum + 0.3% Triton X‐100 in PBS for 1 h. Primary antibodies were applied overnight at 4°C: IGF‐1 (NOVUS, SPM406, 1:200), SLC25A33 (Bioss, bs‐21231R, 1:200), PDGFRβ (CST, #3169, 1:200), E‐cadherin (CST, #14472, 1:200), α‐SMA (Bioss, bs‐10196R, 1:200), TGFβ1 (Bioworld, BS80030, 1:50), p‐Smad2 (Bioworld, bs‐3419R, 1:500).

    Techniques: Expressing, In Vivo, Immunofluorescence, Staining, Knockdown, Over Expression, Control

    Exogenous IGF‐1 rescues blood‐labyrinth barrier integrity and improves hearing function in aged mice. (A) TEM images reveal ultrastructural changes in the stria vascularis. In the IGF‐1‐inhibited group, pericytes exhibit abnormal morphology, loose association with endothelial cells, and widened tight junctions (yellow arrows). These defects are ameliorated by exogenous IGF‐1 administration. (B) Click‐evoked ABR thresholds are significantly elevated in IGF‐1‐suppressed mice but partially rescued by IGF‐1 supplementation. (C–E) At 12 kHz, ABR thresholds are significantly lower in the IGF‐1‐treated group compared to control and suppressed groups, indicating improved auditory sensitivity. (F) Proposed model of IGF‐1/SLC25A33‐mediated regulation of pericyte phenotype and BLB integrity in age‐related hearing loss. Under physiological conditions, pericytes maintain a quiescent state characterized by low α‐SMA and high E‐cadherin expression, contributing to BLB stability. With aging, declining IGF‐1 levels lead to reduced SLC25A33 expression, resulting in mtROS accumulation and activation of the TGF‐β/Smad2 signaling pathway. This drives pericyte transition toward a contractile, pro‐fibrotic phenotype (high α‐SMA, low E‐cadherin), disrupting BLB integrity and promoting cochlear dysfunction. Targeting this axis may offer therapeutic potential for ARHL. Control: wild‐type C57BL/6J mice without treatment; IGF‐1 (−): mice treated with NVP‐AEW541; IGF‐1 (+): mice treated with recombinant IGF‐1. Data are mean ± SEM; n = 6 mice.

    Journal: Aging Cell

    Article Title: IGF ‐1/ SLC25A33 Maintains Blood‐Labyrinth Barrier Integrity by Suppressing TGF ‐β/Smad2‐Mediated Pericyte Activation in Age‐Related Hearing Loss

    doi: 10.1111/acel.70712

    Figure Lengend Snippet: Exogenous IGF‐1 rescues blood‐labyrinth barrier integrity and improves hearing function in aged mice. (A) TEM images reveal ultrastructural changes in the stria vascularis. In the IGF‐1‐inhibited group, pericytes exhibit abnormal morphology, loose association with endothelial cells, and widened tight junctions (yellow arrows). These defects are ameliorated by exogenous IGF‐1 administration. (B) Click‐evoked ABR thresholds are significantly elevated in IGF‐1‐suppressed mice but partially rescued by IGF‐1 supplementation. (C–E) At 12 kHz, ABR thresholds are significantly lower in the IGF‐1‐treated group compared to control and suppressed groups, indicating improved auditory sensitivity. (F) Proposed model of IGF‐1/SLC25A33‐mediated regulation of pericyte phenotype and BLB integrity in age‐related hearing loss. Under physiological conditions, pericytes maintain a quiescent state characterized by low α‐SMA and high E‐cadherin expression, contributing to BLB stability. With aging, declining IGF‐1 levels lead to reduced SLC25A33 expression, resulting in mtROS accumulation and activation of the TGF‐β/Smad2 signaling pathway. This drives pericyte transition toward a contractile, pro‐fibrotic phenotype (high α‐SMA, low E‐cadherin), disrupting BLB integrity and promoting cochlear dysfunction. Targeting this axis may offer therapeutic potential for ARHL. Control: wild‐type C57BL/6J mice without treatment; IGF‐1 (−): mice treated with NVP‐AEW541; IGF‐1 (+): mice treated with recombinant IGF‐1. Data are mean ± SEM; n = 6 mice.

    Article Snippet: Sections were blocked in 10% goat serum + 0.3% Triton X‐100 in PBS for 1 h. Primary antibodies were applied overnight at 4°C: IGF‐1 (NOVUS, SPM406, 1:200), SLC25A33 (Bioss, bs‐21231R, 1:200), PDGFRβ (CST, #3169, 1:200), E‐cadherin (CST, #14472, 1:200), α‐SMA (Bioss, bs‐10196R, 1:200), TGFβ1 (Bioworld, BS80030, 1:50), p‐Smad2 (Bioworld, bs‐3419R, 1:500).

    Techniques: Morphology, Control, Sensitivity, Expressing, Stability, Activation Assay, Recombinant

    Demonstration of the effect of aPRP or PRGF on TGF-β and PDGF-BB expression in HCs and OACs at 2 or 3 h by ELISA. (A–D) TGF-β and (E–H) PDGF-BB expressions of 2.7% aPRP, 1.8% PGRF, or 4.3% L-PRP-administered HCs and OACs are given as mean standard deviation graphs for each time point in comparison with the control groups. One-way analysis of variance (ANOVA), Tukey’s HSD post hoc test (*): p < 0.05.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Activated platelet rich plasma modulates the proliferation, apoptosis and matrix synthesis driven by growth factors in osteoarthritic chondrocytes: an in vitro study

    doi: 10.3389/fbioe.2026.1940844

    Figure Lengend Snippet: Demonstration of the effect of aPRP or PRGF on TGF-β and PDGF-BB expression in HCs and OACs at 2 or 3 h by ELISA. (A–D) TGF-β and (E–H) PDGF-BB expressions of 2.7% aPRP, 1.8% PGRF, or 4.3% L-PRP-administered HCs and OACs are given as mean standard deviation graphs for each time point in comparison with the control groups. One-way analysis of variance (ANOVA), Tukey’s HSD post hoc test (*): p < 0.05.

    Article Snippet: TGF-β1 (#E-EL-H1657, Elabscience, Wuhan, China) and PDGF-BB (#E-EL-H1577, Elabscience, Wuhan, China) levels in the cell supernatant of OACs and HCs were evaluated by ELISA.

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Standard Deviation, Comparison, Control, Analysis

    Flow diagram illustrates the overall design and study outcomes. Activated PRP at lower EC50 promotes OAC proliferation and apoptosis and induces collagen type-II, aggrecan, TGF-β and PDGF-BB expressions in OACs. Activated PRP may improve osteoarthritic joint function. This figure was created with AI assistance under the authors’ supervision. All conceptual content and final approval were provided by the authors.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Activated platelet rich plasma modulates the proliferation, apoptosis and matrix synthesis driven by growth factors in osteoarthritic chondrocytes: an in vitro study

    doi: 10.3389/fbioe.2026.1940844

    Figure Lengend Snippet: Flow diagram illustrates the overall design and study outcomes. Activated PRP at lower EC50 promotes OAC proliferation and apoptosis and induces collagen type-II, aggrecan, TGF-β and PDGF-BB expressions in OACs. Activated PRP may improve osteoarthritic joint function. This figure was created with AI assistance under the authors’ supervision. All conceptual content and final approval were provided by the authors.

    Article Snippet: TGF-β1 (#E-EL-H1657, Elabscience, Wuhan, China) and PDGF-BB (#E-EL-H1577, Elabscience, Wuhan, China) levels in the cell supernatant of OACs and HCs were evaluated by ELISA.

    Techniques: